{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:31:05Z","timestamp":1792855865484,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent advances in imaging technology and increased options of pharmaceutical therapy require that guidelines on the diagnostic criteria and treatment of neovascular age-related macular degeneration (AMD) be updated at regular intervals. These guidelines aim to standardize the management of neovascular AMD based on the latest understanding of its pathophysiology, advancements in diagnostic imaging modalities, and treatment options. The key updates include: (1) a revision of terminology and stage classification, adopting the AMD classifications of atrophic and neovascular, and adding end-stage AMD to the existing early, intermediate, and late stages; (2) the inclusion of pachychoroid in addition to drusen in the initial pathophysiology and pathogenic background; (3) diagnostic criteria defined by the presence of macular neovascularization based on multimodal imaging, including optical coherence tomography (OCT) and OCT angiography; (4) assessment of disease activity based on OCT; and (5) treatment guidance, including prophylaxis and low vision care as well as loading and maintenance phases by use of anti-vascular endothelial growth factor therapy and adjunctive therapies. We hope that these guidelines will be useful for those working in clinical practice in Japan, in other Asian countries, and in countries outside Asia.<\/jats:p>","DOI":"10.1007\/s10384-025-01240-0","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T06:40:46Z","timestamp":1752475246000},"page":"639-660","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Japanese clinical guidelines for neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"69","author":[{"given":"Tomohiro","family":"Iida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Gomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Yasukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yamashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Maruko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Japanese Retina and Vitreous Society Guidelines Committee for Neovascular Age-Related Macular Degeneration","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"1240_CR1","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1097\/IAE.0b013e3182953df4","volume":"33","author":"DJ Warrow","year":"2013","unstructured":"Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013;33:1659\u201372.","journal-title":"Retina"},{"key":"1240_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15\u201322.","journal-title":"Am J Ophthalmol"},{"key":"1240_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020;127:616\u201336.","journal-title":"Ophthalmology"},{"key":"1240_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0039-6257(05)80092-X","volume":"39","author":"AC Bird","year":"1995","unstructured":"Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367\u201374.","journal-title":"Surv Ophthalmol"},{"key":"1240_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3. Ophthalmology. 2018;125:537\u201348.","journal-title":"Ophthalmology"},{"key":"1240_CR6","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0161-6420(00)00409-7","volume":"107","author":"Age-Related Eye Disease Study Research Group","year":"2000","unstructured":"Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. a case-control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology. 2000;107:2224\u201332.","journal-title":"Ophthalmology"},{"key":"1240_CR7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","volume":"120","author":"FL Ferris","year":"2013","unstructured":"Ferris FL, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844\u201351.","journal-title":"Ophthalmology"},{"key":"1240_CR8","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.survophthal.2018.05.005","volume":"63","author":"RF Spaide","year":"2018","unstructured":"Spaide RF, Ooto S, Curcio CA. Subretinal drusenoid deposits AKA pseudodrusen. Surv Ophthalmol. 2018;63:782\u2013815.","journal-title":"Surv Ophthalmol"},{"key":"1240_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10384-017-0556-3","volume":"62","author":"A Tsujikawa","year":"2018","unstructured":"Tsujikawa A, Akagi-Kurashige Y, Yuzawa M, Ishibashi T, Nakanishi H, Nakatani E, et al. Baseline data from a multicenter, 5-year, prospective cohort study of Japanese age-related macular degeneration: an AMD2000 report. Jpn J Ophthalmol. 2018;62:127\u201336.","journal-title":"Jpn J Ophthalmol"},{"key":"1240_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye (Lond). 2019;33:14\u201333.","journal-title":"Eye (Lond)"},{"key":"1240_CR11","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1097\/IAE.0b013e3181be0a83","volume":"29","author":"Y Imamura","year":"2009","unstructured":"Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009;29:1469\u201373.","journal-title":"Retina"},{"key":"1240_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","volume":"35","author":"CE Pang","year":"2015","unstructured":"Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015;35:1\u20139.","journal-title":"Retina"},{"key":"1240_CR13","doi-asserted-by":"publisher","first-page":"18423","DOI":"10.1038\/s41598-020-75451-5","volume":"10","author":"Y Hosoda","year":"2020","unstructured":"Hosoda Y, Miyake M, Yamashiro K, Ooto S, Takahashi A, Oishi A, et al. Deep phenotype unsupervised machine learning revealed the significance of pachychoroid features in etiology and visual prognosis of age-related macular degeneration. Sci Rep. 2020;10:18423.","journal-title":"Sci Rep"},{"key":"1240_CR14","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1038\/s41598-022-08666-3","volume":"12","author":"H Matsumoto","year":"2022","unstructured":"Matsumoto H, Hoshino J, Mukai R, Nakamura K, Kishi S, Akiyama H. Clinical characteristics and pachychoroid incidence in Japanese patients with neovascular age-related macular degeneration. Sci Rep. 2022;12:4492.","journal-title":"Sci Rep"},{"key":"1240_CR15","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.1038\/s41598-023-33936-z","volume":"13","author":"A Kuranami","year":"2023","unstructured":"Kuranami A, Maruko R, Maruko I, Hasegawa T, Iida T. Pachychoroid neovasculopathy has clinical properties that differ from conventional neovascular age-related macular degeneration. Sci Rep. 2023;13:7379.","journal-title":"Sci Rep"},{"key":"1240_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.oret.2017.08.016","volume":"2","author":"A Takahashi","year":"2018","unstructured":"Takahashi A, Ooto S, Yamashiro K, Tamura H, Oishi A, Miyata M, et al. Pachychoroid geographic atrophy: clinical and genetic characteristics. Ophthalmol Retina. 2018;2:295\u2013305.","journal-title":"Ophthalmol Retina."},{"key":"1240_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ng.3448","volume":"48","author":"LG Fritsche","year":"2016","unstructured":"Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48:134\u201343.","journal-title":"Nat Genet"},{"key":"1240_CR18","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1038\/ncomms7063","volume":"6","author":"CY Cheng","year":"2015","unstructured":"Cheng CY, Yamashiro K, Chen LJ, Ahn J, Huang L, Huang L, et al. New loci and coding variants confer risk for age-related macular degeneration in East Asians. Nat Commun. 2015;6:6063.","journal-title":"Nat Commun"},{"key":"1240_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ophtha.2013.11.020","volume":"121","author":"A Miki","year":"2014","unstructured":"Miki A, Kondo N, Yanagisawa S, Bessho H, Honda S, Negi A. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology. 2014;121:1067\u201372.","journal-title":"Ophthalmology"},{"key":"1240_CR20","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.1073\/pnas.1802212115","volume":"115","author":"Y Hosoda","year":"2018","unstructured":"Hosoda Y, Yoshikawa M, Miyake M, Tabara Y, Ahn J, Woo SJ, et al. CFH and VIPR2 as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy. Proc Natl Acad Sci USA. 2018;115:6261\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1240_CR21","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.oret.2019.05.025","volume":"3","author":"Y Hosoda","year":"2019","unstructured":"Hosoda Y, Yamashiro K, Miyake M, Ooto S, Oishi A, Miyata M, et al. Predictive genes for the prognosis of central serous chorioretinopathy. Ophthalmol Retina. 2019;3:985\u201392.","journal-title":"Ophthalmol Retina."},{"issue":"542\u20138","key":"1240_CR22","volume":"154","author":"H Tamura","year":"2012","unstructured":"Tamura H, Tsujikawa A, Yamashiro K, Akagi-Kurashige Y, Nakata I, Nakanishi H, et al. Association of ARMS2 genotype with bilateral involvement of exudative age-related macular degeneration. Am J Ophthalmol. 2012;154(542\u20138): e1.","journal-title":"Am J Ophthalmol"},{"key":"1240_CR23","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1167\/iovs.14-16020","volume":"56","author":"M Miyake","year":"2015","unstructured":"Miyake M, Yamashiro K, Tamura H, Kumagai K, Saito M, Sugahara-Kuroda M, et al. The contribution of genetic architecture to the 10-year incidence of age-related macular degeneration in the fellow eye. Invest Ophthalmol Vis Sci. 2015;56:5353\u201361.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1240_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ophtha.2006.10.040","volume":"114","author":"R Klein","year":"2007","unstructured":"Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114:253\u201362.","journal-title":"Ophthalmology"},{"key":"1240_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/01.iae.0000249386.63482.05","volume":"27","author":"T Sato","year":"2007","unstructured":"Sato T, Kishi S, Watanabe G, Matsumoto H, Mukai R. Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy. Retina. 2007;27:589\u201394.","journal-title":"Retina"},{"key":"1240_CR26","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.oret.2021.04.002","volume":"5","author":"KY Chong Teo","year":"2021","unstructured":"Chong Teo KY, Sadda SR, Gemmy Cheung CM, Chakravarthy U, Staurenghi G, Invernizzi A, et al. Non-ICGA treatment criteria for Suboptimal Anti-VEGF response for polypoidal choroidal vasculopathy: APOIS PCV workgroup report 2. Ophthalmol Retina. 2021;5:945\u201353.","journal-title":"Ophthalmol Retina."},{"key":"1240_CR27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","volume":"128","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Lai TYY, Teo K, Ruamviboonsuk P, Chen SJ, Kim JE, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup. Ophthalmology. 2021;128:443\u201352.","journal-title":"Ophthalmology"},{"key":"1240_CR28","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1097\/IAE.0000000000002760","volume":"40","author":"A Fujita","year":"2020","unstructured":"Fujita A, Kataoka K, Takeuchi J, Nakano Y, Horiguchi E, Kaneko H, et al. Diagnostic characteristics of polypoidal choroidal vasculopathy based on B-scan swept-source optical coherence tomography angiography and its interrater agreement compared with indocyanine green angiography. Retina. 2020;40:2296\u2013303.","journal-title":"Retina"},{"key":"1240_CR29","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/IAE.0000000000001689","volume":"38","author":"RF Spaide","year":"2018","unstructured":"Spaide RF. Disease expression in nonexudative age-related macular degeneration varies with choroidal thickness. Retina. 2018;38:708\u201316.","journal-title":"Retina"},{"key":"1240_CR30","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.ophtha.2007.11.015","volume":"115","author":"R Kawasaki","year":"2008","unstructured":"Kawasaki R, Wang JJ, Ji G, Taylor B, Oizumi T, Daimon M, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology. 2008;115:1376\u201381.","journal-title":"Ophthalmology"},{"key":"1240_CR31","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/j.ophtha.2009.04.017","volume":"116","author":"M Yasuda","year":"2009","unstructured":"Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology. 2009;116:2135\u201340.","journal-title":"Ophthalmology"},{"issue":"1002\u20139","key":"1240_CR32","volume":"156","author":"I Nakata","year":"2013","unstructured":"Nakata I, Yamashiro K, Nakanishi H, Akagi-Kurashige Y, Miyake M, Tsujikawa A, et al. Prevalence and characteristics of age-related macular degeneration in the Japanese population: the Nagahama study. Am J Ophthalmol. 2013;156(1002\u20139): e2.","journal-title":"Am J Ophthalmol"},{"key":"1240_CR33","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1001\/jama.294.24.3101","volume":"294","author":"R van Leeuwen","year":"2005","unstructured":"van Leeuwen R, Boekhoorn S, Vingerling JR, Witteman JC, Klaver CC, Hofman A, et al. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA. 2005;294:3101\u20137.","journal-title":"JAMA"},{"key":"1240_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ophtha.2020.08.018","volume":"128","author":"E Agron","year":"2021","unstructured":"Agron E, Mares J, Clemons TE, Swaroop A, Chew EY, Keenan TDL, et al. Dietary nutrient intake and progression to late age-related macular degeneration in the age-related eye disease studies 1 and 2. Ophthalmology. 2021;128:425\u201342.","journal-title":"Ophthalmology"},{"key":"1240_CR35","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"RD Jager","year":"2008","unstructured":"Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606\u201317.","journal-title":"N Engl J Med"},{"key":"1240_CR36","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","volume":"119","author":"Age-Related Eye Disease Study Research Group","year":"2001","unstructured":"Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417\u201336.","journal-title":"Arch Ophthalmol"},{"key":"1240_CR37","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.2013.4997","volume":"309","author":"Age-Related Eye Disease Study 2 Research Group","year":"2013","unstructured":"Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309:2005\u201315.","journal-title":"JAMA"},{"key":"1240_CR38","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/jamaophthalmol.2022.1640","volume":"140","author":"EY Chew","year":"2022","unstructured":"Chew EY, Clemons TE, Agron E, Domalpally A, Keenan TDL, Vitale S, et al. Long-term outcomes of adding lutein\/zeaxanthin and omega-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmol. 2022;140:692\u20138.","journal-title":"JAMA Ophthalmol."},{"key":"1240_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264703","volume":"17","author":"Y Oshima","year":"2022","unstructured":"Oshima Y, Shinojima A, Sawa M, Mori R, Sekiryu T, Kato A, et al. Progression of age-related macular degeneration in eyes with abnormal fundus autofluorescence in a Japanese population: JFAM study report 3. PLoS ONE. 2022;17: e0264703.","journal-title":"PLoS ONE"},{"key":"1240_CR40","first-page":"CD005139","volume":"8","author":"SD Solomon","year":"2014","unstructured":"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;8:CD005139.","journal-title":"Cochrane Database Syst Rev"},{"key":"1240_CR41","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"1240_CR42","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"1240_CR43","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser P, Nguyen Q, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"1240_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"1240_CR45","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"1240_CR46","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352.","journal-title":"Lancet"},{"key":"1240_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-319090","author":"Y Ogura","year":"2021","unstructured":"Ogura Y, Jaffe GJ, Cheung CMG, Kokame GT, Iida T, Takahashi K, et al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol. 2021. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319090.","journal-title":"Br J Ophthalmol"},{"key":"1240_CR48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.oret.2021.05.003","volume":"6","author":"M Singer","year":"2022","unstructured":"Singer M, Albini TA, Seres A, Baumal CR, Parikh S, Gale R, et al. Clinical characteristics and outcomes of eyes with intraocular inflammation after brolucizumab: post hoc analysis of HAWK and HARRIER. Ophthalmol Retina. 2022;6:97\u2013108.","journal-title":"Ophthalmol Retina."},{"key":"1240_CR49","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET Study: a randomized clinical trial. JAMA Ophthalmol. 2018;136:786\u201393.","journal-title":"JAMA Ophthalmol."},{"key":"1240_CR50","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Comparison of age-related macular degeneration treatments trials research group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388\u201398.","journal-title":"Ophthalmology"},{"key":"1240_CR51","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046\u201356.","journal-title":"Ophthalmology"},{"key":"1240_CR52","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292\u20139.","journal-title":"Ophthalmology"},{"key":"1240_CR53","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"MG Maguire","year":"2016","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials Research Group, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1751\u201361.","journal-title":"Ophthalmology"},{"key":"1240_CR54","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","volume":"1","author":"CC Wykoff","year":"2017","unstructured":"Wykoff CC, Ou WC, Brown DM, Croft DE, Wang R, Payne JF, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration 2-year results of the trex-amd study. Ophthalmol Retina. 2017;1:314\u201321.","journal-title":"Ophthalmol Retina."},{"key":"1240_CR55","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR\u202f: a randomized controlled trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"1240_CR56","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.oret.2020.03.010","volume":"4","author":"I Maruko","year":"2020","unstructured":"Maruko I, Ogasawara M, Yamamoto A, Itagaki K, Hasegawa T, Arakawa H, et al. Two-year outcomes of treat-and-extend intravitreal aflibercept for exudative age-related macular degeneration: a prospective study. Ophthalmology Retina. 2020;4:767\u201376.","journal-title":"Ophthalmology Retina."},{"key":"1240_CR57","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41433-022-02020-7","volume":"37","author":"D Rosenberg","year":"2023","unstructured":"Rosenberg D, Deonarain DM, Gould J, Sothivannan A, Phillips MR, Sarohia GS, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). 2023;37:6\u201316.","journal-title":"Eye (Lond)"},{"key":"1240_CR58","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/01.iae.0000233647.78726.46","volume":"27","author":"Y Hirami","year":"2007","unstructured":"Hirami Y, Tsujikawa A, Otani A, Yodoi Y, Aikawa H, Mandai M, et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina. 2007;27:335\u201341.","journal-title":"Retina"},{"key":"1240_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ophtha.2007.02.031","volume":"115","author":"F Gomi","year":"2008","unstructured":"Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008;115:141\u20136.","journal-title":"Ophthalmology"},{"key":"1240_CR60","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","volume":"35","author":"F Gomi","year":"2015","unstructured":"Gomi F, Oshima Y, Mori R, Kano M, Saito M, Yamashita A, et al. Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: The Fujisan Study. Retina. 2015;35:1569\u201376.","journal-title":"Retina"},{"key":"1240_CR61","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K, Wong TY, Chen L-JJ, Ruamviboonsuk P, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA ophthalmology. 2017;135:1206\u201313.","journal-title":"JAMA ophthalmology"},{"key":"1240_CR62","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10384-020-00722-7","volume":"64","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Mukai R, Kikuchi Y, Morimoto M, Akiyama H. One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions. Jpn J Ophthalmol. 2020;64:203\u20139.","journal-title":"Jpn J Ophthalmol"},{"key":"1240_CR63","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00417-020-04661-4","volume":"258","author":"Y Kitajima","year":"2020","unstructured":"Kitajima Y, Maruyama-Inoue M, Ito A, Sato S, Inoue T, Yamane S, et al. One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol. 2020;258:1279\u201385.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1240_CR64","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3390\/jcm10102168","volume":"10","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Mori R, Wakatsuki Y, Onoe H, Kawamura A, Nakashizuka H. Two-thirds dose photodynamic therapy for pachychoroid neovasculopathy. J Clin Med. 2021;10:2168.","journal-title":"J Clin Med"},{"key":"1240_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248760","volume":"16","author":"A Miki","year":"2021","unstructured":"Miki A, Kusuhara S, Otsuji T, Kawashima Y, Miki K, Imai H, et al. Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PLoS ONE. 2021;16: e0248760.","journal-title":"PLoS ONE"},{"key":"1240_CR66","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1038\/s41433-021-01418-z","volume":"35","author":"T Hikichi","year":"2021","unstructured":"Hikichi T, Kubo N, Yamauchi M. One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovasculopathy. Eye (Lond). 2021;35:3367\u201375.","journal-title":"Eye (Lond)"},{"key":"1240_CR67","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06030-3","author":"J Takeuchi","year":"2023","unstructured":"Takeuchi J, Ota H, Nakano Y, Horiguchi E, Taki Y, Ito Y, et al. Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol. 2023. https:\/\/doi.org\/10.1007\/s00417-023-06030-3.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1240_CR68","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1001\/archopht.1991.01080080069030","volume":"109","author":"Macular Photocoagulation Study Group","year":"1991","unstructured":"Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. five-year results from randomized clinical trials Macular Photocoagulation Study Group. Arch Ophthalmol. 1991;109:1109\u201314.","journal-title":"Arch Ophthalmol"},{"key":"1240_CR69","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0021-5155(03)00042-X","volume":"47","author":"M Yuzawa","year":"2003","unstructured":"Yuzawa M, Mori R, Haruyama M. A study of laser photocoagulation for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2003;47:379\u201384.","journal-title":"Jpn J Ophthalmol"},{"key":"1240_CR70","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/archopht.116.10.1326","volume":"116","author":"M Ohji","year":"1998","unstructured":"Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol. 1998;116:1326\u201332.","journal-title":"Arch Ophthalmol"},{"key":"1240_CR71","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0002-9394(00)00734-0","volume":"131","author":"CL Haupert","year":"2001","unstructured":"Haupert CL, McCuen BW 2nd, Jaffe GJ, Steuer ER, Cox TA, Toth CA, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol. 2001;131:208\u201315.","journal-title":"Am J Ophthalmol"},{"key":"1240_CR72","unstructured":"Heriot WJ. Intravitreal gas and tPA: an outpatient procedure for submacular hemorrhage. Vail Vitrectomy Meeting; Veil, CO1996."},{"key":"1240_CR73","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ajo.2014.12.020","volume":"159","author":"S Kimura","year":"2015","unstructured":"Kimura S, Morizane Y, Hosokawa M, Shiode Y, Kawata T, Doi S, et al. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator. Am J Ophthalmol. 2015;159:683\u20139.","journal-title":"Am J Ophthalmol"},{"key":"1240_CR74","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.ophtha.2016.01.035","volume":"123","author":"Y Kitagawa","year":"2016","unstructured":"Kitagawa Y, Shimada H, Mori R, Tanaka K, Yuzawa M. Intravitreal tissue plasminogen activator, ranibizumab, and gas injection for submacular hemorrhage in polypoidal choroidal vasculopathy. Ophthalmology. 2016;123:1278\u201386.","journal-title":"Ophthalmology"},{"key":"1240_CR75","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/138945011794182746","volume":"12","author":"EM Becerra","year":"2011","unstructured":"Becerra EM, Morescalchi F, Gandolfo F, Danzi P, Nascimbeni G, Arcidiacono B, et al. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr Drug Targets. 2011;12:149\u201372.","journal-title":"Curr Drug Targets"},{"key":"1240_CR76","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1097\/IAE.0000000000003556","volume":"42","author":"FG Holz","year":"2022","unstructured":"Holz FG, Iida T, Maruko I, Sadda SR. A consensus on risk mitigation for brolucizumab in neovascular age-related macular degeneration: patient selection, evaluation, and treatment. Retina. 2022;42:1629\u201337.","journal-title":"Retina"},{"key":"1240_CR77","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Age-related macular degeneration preferred practice pattern(R). Ophthalmology. 2020;127:P1-65.","journal-title":"Ophthalmology"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01240-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01240-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01240-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T12:28:23Z","timestamp":1757248103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01240-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01240-0","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T. Iida, Grants (NIDEK, Topcon, Santen, Novartis, Senju, Alcon, HOYA, AMO), Consulting fees (Bayer, Chugai, Novartis, Boehringer Ingelheim, Janssen, Senju, Kyowa Kirin), Payment or honoraria for lectures (Bayer, Novartis, Alcon, Santen, Senju, Topcon, Chugai, Canon, Nidek, Otsuka, Nikon), Patents planned, issued or pending (Topcon) ; F. Gomi, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Bayer, Novartis, Chugai, Santen, Senju, Canon, Nidek, JINS, Kyowa Kirin); T. Yasukawa, Research Grant (Bayer, Santen, Chugai, Senju, Wakamoto), Consulting fees (Wakamoto), Honoraria for speakers (Novartis), Honoraria for speakers or their chairman (Bayer, Santen, Senju, Chugai), Participation on a Data Safety Monitoring Board or Advisory Board (Chugai); K. Yamashiro, Payment or honoraria for lectures (Novartis, Bayer, Santen, Senju, Chugai, Alcon, Kowa, Otsuka, HOYA, NIDEK, Asahi Kasei), Payment or honoraria for Consultant (Boehringer Ingelheim); S. Honda, Grants or contracts (Santen, Alcon, Senju, Chugai), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Santen, Chugai, Senju, Johnson & Johnson, Novartis); I. Maruko, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Bayer, Novartis, Alcon, Santen, Senju, Topcon, Chugai, Canon, Nidek, Nikon), Patents planned, issued or pending (Jpn-patent (#7288276)); K. Kataoka, Grants (Chugai), Honoraria for lectures (Bayer, Chugai, Santen, Novartis, Senju, Boehringer Ingelheim, Canon, ZEISS), Participation on advisory Board (Chugai); Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid (Bayer).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}